- Home
- Investors
- Annual Review 2006
- Our strategy at a glance
Our strategy at a glance
Helping people do more, feel better and live longer
Our business is built on four strategic objectives and we made good progress on all of them in 2006.
Cancer: This time it’s personal
In 2006, we made excellent progress with our pipeline, particularly with medicines for cancer. Our unique structure for R&D lets innovation thrive and is delivering new breakthrough treatments for patients.
Diabetes: Life is bittersweet
In 2006, our key products continued to grow, including the Avandia group of products for diabetes. Our medicines, vaccines and consumer healthcare products meet patient needs and deliver value for those paying – individuals, organisations or governments.
Malaria: Reality bites
In 2006, we continued to provide products such as antimalarials, antiretrovirals and vaccines at preferential prices. We are finding innovative ways to bring medicines, vaccines and health education to patients in all countries, including those suffering from epidemics and neglected diseases.
Improving access to medicines, both in the developed and the developing world.
People: Joined-up thinking
In 2006, our leadership opinion survey showed that 90 per cent of managers are proud to work for GSK. People thrive in our distinctive culture of high performance, responsible business practices and openness to new ideas.
Being the best place for the best people to do their best work.
All of these objectives are underpinned by a commitment to run our business in a responsible way.
Responsibility: Now wash your hands?
We will never step aside from our responsibilities. In 2006, we carried out many projects which are making a real difference to communities worldwide, including expanding our hand-washing education programme (PHASE) to more countries. We believe in running our business responsibly and in playing our part for the benefit of society.
Running our business responsibly and playing our part in the community.
Print-friendly version